@Article{,
AUTHOR = {Serge Carrier},
TITLE = {Pharmacology of phosphodiesterase 5 inhibitors},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {10},
YEAR = {2003},
NUMBER = {Suppl.1},
PAGES = {12--16},
URL = {http://www.techscience.com/CJU/v10nSuppl.1/63394},
ISSN = {1488-5581},
ABSTRACT = {The phosphodiesterase enzymes, of at least 11 types, are
ubiquitous throughout the body, and perform a variety
of functions. Phosphodiesterase type 5 (PDE5) is the
predominant enzyme in the corpus cavernosum, and
plays a crucial role in penile erection. Inhibitors of PDE5
are the most effective oral agents in the treatment of
erectile dysfunction. Sildenafil, tadalafil, and vardenafil
are all potent inhibitors of PDE5 and show the same
mechanism of action, although they have some
pharmacological differences that may translate into
varying clinical effects.},
DOI = {}
}